Novocure Ltd

NASDAQ NVCR

Data sourced from iex and EODHD
Download Data

Novocure Ltd Gross Profit for the Trailing 12 Months (TTM) ending March 31, 2024: USD 393.30 M

Novocure Ltd Gross Profit is USD 393.30 M for the Trailing 12 Months (TTM) ending March 31, 2024, a -3.06% change year over year. Gross profit is the difference between revenue and the cost of revenue, representing the profit earned from core business operations.
  • Novocure Ltd Gross Profit for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 405.72 M, a -3.78% change year over year.
  • Novocure Ltd Gross Profit for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 421.66 M, a 0.67% change year over year.
  • Novocure Ltd Gross Profit for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 418.84 M, a 46.17% change year over year.
  • Novocure Ltd Gross Profit for the Trailing 12 Months (TTM) ending March 31, 2020 was USD 286.55 M, a 52.72% change year over year.
NASDAQ: NVCR

Novocure Ltd

CEO Mr. William F. Doyle
IPO Date Oct. 2, 2015
Location Jersey
Headquarters No. 4 The Forum, Saint Helier, Jersey, JE2 4UF
Employees 1,453
Sector Healthcare
Industry Medical devices
Description

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Similar companies

INMD

InMode Ltd

NA

NA

IRTC

iRhythm Technologies Inc

NA

NA

StockViz Staff

September 16, 2024

Any question? Send us an email